Ahmedabad (Gujarat) [India], January 30: Zydus Lifesciences Ltd., a global innovation-driven healthcare company announced that it has launched Relugolix under the brand name, Rexigo™. This is the first and only oral once-a-day therapy for testosterone suppression in patients with advan
Salt Lake City (Utah) [US], May 3 (ANI): Researchers from SWOG Cancer Research Network have significantly extended median survival for patients with hormone-sensitive metastatic prostate cancer. This result comes from a large randomized clinical trial aimed at testing a new treatment for the
Washington, Aug. 9 (ANI): In a retrospective study, the researchers have found that African-American men, who were treated with ADT (androgen deprivation therapy), had a 77 percent higher risk of death when compared to non-African American men.